Shots:

• The P-III VANISH-303 evaluates ibrexafungerp vs PBO in patients with VVC & P-II DOVE studies assess ibrexafungerp vs fluconazole for the same indication. The results were published in America’s Clinical Infectious Diseases
• In the P-III study- the therapy was superior in completely resolving signs & symptoms of VVC @10 Day (50.5% vs 28.6%); superior mycological eradication (49.5% vs 19.4%); symptom resolution was sustained & further increased (59.6% vs 44.9%). Post hoc analysis showed similar rates of clinical cure & improvement (54.8% & 63.4%)- respectively
• In the P-II DOVE study- ibrexafungerp showed similar efficacy to SC @10 Day with sustained efficacy @25 Day follow-up- was well-tolerated

 ­ | Ref: Scynexis | Image: Scynexis